VWF and COVID-19: Studies by a research group at Yale University led by Prof Hwa have demonstrated the role of endotheliopathy to COVID-19 severity, and suggested increased circulating levels of markers of endothelial cell damage, including thrombomodulin, angiopoietin 2, and vWF, are positively correlated with increased mortality in COVID-19 patients [138].